Sickle cell disease, despite its recognition as a severely debilitating genetic condition
affecting hundreds of thousands of neonates throughout the world each year, was not a …

Acute pain, the most prominent complication of sickle cell disease (SCD), results from vaso-
occlusion triggered by sickling of deoxygenated red blood cells (RBCs). Concentration of 2 …

Hydroxyurea, the first approved drug for sickle cell disease, decreases sickle hemoglobin
polymerization by inducing fetal hemoglobin. Its effects in young children are excellent; …

Polymerization of deoxygenated sickle hemoglobin (HbS) leads to erythrocyte sickling.
Enhancing activity of the erythrocyte glycolytic pathway has anti-sickling potential as this …

Sickle cell disease (SCD) is a hereditary hematological disease with high morbidity and
mortality rates worldwide. Despite being monogenic, SCD patients display a plethora of …

We characterized the human β-like globin transgenes in two mouse models of sickle cell
disease (SCD) and tested a genome-editing strategy to induce red blood cell fetal …

Sickle cell disease (SCD) refers to a group of inherited hemoglobin disorders in which sickle
red blood cells display altered deformability, leading to a significant burden of acute and …

Human red blood cells (RBCs) have a circulatory lifespan of about four months. Under
constant oxidative and mechanical stress, but devoid of organelles and deprived of …

Ex vivo cellular system that accurately replicates sickle cell disease and β-thalassemia
characteristics is a highly sought-after goal in the field of erythroid biology. In this study, we …

With increasing survival, cumulative complications of sickle cell disease (SCD), which
develop insidiously over time, are becoming more apparent and common in older patients …